Nimotop (Nimodipine) Capsules: Uses, Dosage, Safety and Interactions

Nimotop is a prescription medicine containing nimodipine, a calcium-channel blocker used after aneurysmal subarachnoid hemorrhage, a life-threatening type of bleeding around the brain. Its purpose is to improve neurological outcome by reducing the incidence and severity of ischemic deficits associated with this condition. Treatment is part of specialist hospital care and is not a general remedy for headache, dizziness, memory problems, high blood pressure, or routine migraine.

Subarachnoid hemorrhage is a medical emergency. Sudden severe headache, loss of consciousness, seizure, vomiting, neck stiffness, new weakness, speech difficulty, or confusion requires emergency services. Nimotop should be initiated and supervised by clinicians experienced in neurocritical care, with monitoring of blood pressure, neurological status, swallowing ability, and other medicines.

Patients who have a valid prescription may buy Nimotop through a regulated pharmacy when treatment is arranged by the specialist team. The Nimotop price may differ by supply format, quantity, manufacturer, pharmacy, and insurance coverage. Access, dose, and route should always follow the hospital or prescriber’s instructions; purchasing decisions must not delay urgent emergency assessment.

Indications

Nimotop is indicated to improve neurological outcome by reducing ischemic deficits after subarachnoid hemorrhage from a ruptured intracranial aneurysm. It is not approved as a routine treatment for hypertension, prevention of ordinary headache, dementia, learning difficulties, or nonspecific cerebral circulation symptoms. Its use should be tied to the defined neurological condition and managed in the appropriate clinical setting.

Nimodipine does not remove the need for aneurysm treatment, neurosurgical or endovascular evaluation, intensive monitoring, management of hydrocephalus or seizures when present, and rehabilitation planning. Carers should follow the treating team’s instructions exactly and report new drowsiness, confusion, weakness, chest symptoms, fainting, poor intake, vomiting, or medication-administration problems promptly.

Dosage

Take Nimotop only as directed by the treating specialist. Oral nimodipine regimens after aneurysmal subarachnoid hemorrhage commonly use 60 mg every four hours for a defined treatment period, but the schedule, formulation, and route must be individualized by the clinical team. It is generally given on an empty stomach, one hour before or two hours after meals, with water. Do not alter the timing, dose, or route.

Nimotop capsules are commonly supplied as 30 mg liquid-filled capsules. Patients with a valid prescription may buy Nimotop 30 mg only when that strength and schedule are prescribed by the care team. Patients with a valid prescription may buy Nimotop 30 mg from a regulated source for the specified treatment episode. The Nimotop price of another form is not a reason to change capsules to a different route or formulation.

Nimodipine capsules must never be injected intravenously, and their contents must never be administered by intravenous or other parenteral routes. This can cause serious or fatal adverse events. If swallowing is not possible, healthcare professionals should use the approved institution-specific administration method. If an oral dose is missed, contact the treating team for instructions rather than doubling the next dose.

Safety Information

Do not use Nimotop if there has been a serious hypersensitivity reaction to nimodipine or an ingredient in the product. Tell the prescriber about low blood pressure, slow heart rate, heart failure, recent myocardial infarction, liver disease, kidney disease, brain swelling, pregnancy, breastfeeding, and all current medicines. Liver impairment can increase nimodipine exposure and may require close monitoring or a dose adjustment.

Nimodipine can lower blood pressure and cause dizziness, fainting, flushing, headache, weakness, nausea, slow or fast heartbeat, or swelling. In hospital, blood pressure monitoring is important. Seek urgent help for fainting, chest pain, shortness of breath, unusual weakness, rapid worsening of neurological symptoms, severe dizziness, swelling of the face or throat, or difficulty breathing. Patients who buy Nimotop with a valid prescription should keep it in the original packaging, protected from light, and use it only under the treating team’s direction.

Interactions

Nimodipine is metabolized through CYP3A4. Strong CYP3A4 inhibitors, including certain azole antifungals, macrolide antibiotics, HIV medicines, and some antidepressants, can raise nimodipine concentrations and increase hypotension risk. Strong inducers, including rifampin, carbamazepine, phenytoin, phenobarbital, and St John’s wort, can reduce levels and may make treatment ineffective. Grapefruit juice can increase nimodipine exposure and should be avoided.

Other blood-pressure-lowering medicines, beta blockers, cimetidine, valproic acid, and calcium-channel blockers require clinical review because additive cardiovascular effects or increased exposure may occur. Give the full medication list to the specialist and pharmacist. The Nimotop price is not a measure of safety, and an interaction check is essential before any medicine or supplement is added.

Medical disclaimer: This content is informational and does not replace advice, diagnosis, or treatment from a licensed healthcare professional. Nimotop is a prescription medicine, and patients should follow their prescriber’s directions and seek professional advice for questions about their treatment.